Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID Reference, 5th edition, 486 pages Free download

Prostate Cancer

Free Subscription Articles published in Oncogene Retrieve available abstracts of 123 articles: HTML format

Single Articles

November 2020
1. BUCKUP M, Rice MA, Hsu EC, Garcia-Marques F, et al
   Plectin is a regulator of prostate cancer growth and metastasis.
   Oncogene. 2020 Nov 20. pii: 10.1038/s41388-020-01557.
   PubMed     Abstract available
   
   
   
2. SINGH KB, Hahm ER, Kim SH, Wendell SG, et al
   A novel metabolic function of Myc in regulation of fatty acid synthesis in prostate cancer.
   Oncogene. 2020 Nov 16. pii: 10.1038/s41388-020-01553.
   PubMed     Abstract available
   
   
   October 2020
3. WANG YA, Sfakianos J, Tewari AK, Cordon-Cardo C, et al
   Molecular tracing of prostate cancer lethality.
   Oncogene. 2020 Oct 12. pii: 10.1038/s41388-020-01496.
   PubMed     Abstract available
   
   
   
4. BHAGIRATH D, Liston M, Patel N, Akoto T, et al
   MicroRNA determinants of neuroendocrine differentiation in metastatic castration-resistant prostate cancer.
   Oncogene. 2020 Oct 9. pii: 10.1038/s41388-020-01493.
   PubMed     Abstract available
   
   
   September 2020
5. ZHU Y, Dalrymple SL, Coleman I, Zheng SL, et al
   Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors.
   Oncogene. 2020 Sep 28. pii: 10.1038/s41388-020-01479.
   PubMed     Abstract available
   
   
   
6. QIAN K, Wang G, Ju L, Liu J, et al
   A novel germline EGFR variant p.R831H causes predisposition to familial CDK12-mutant prostate cancer with tandem duplicator phenotype.
   Oncogene. 2020 Sep 25. pii: 10.1038/s41388-020-01476.
   PubMed     Abstract available
   
   
   
7. LIN SR, Wen YC, Yeh HL, Jiang KC, et al
   EGFR-upregulated LIFR promotes SUCLG2-dependent castration resistance and neuroendocrine differentiation of prostate cancer.
   Oncogene. 2020 Sep 22. pii: 10.1038/s41388-020-01468.
   PubMed     Abstract available
   
   
   
8. WEN S, He Y, Wang L, Zhang J, et al
   Aberrant activation of super enhancer and choline metabolism drive antiandrogen therapy resistance in prostate cancer.
   Oncogene. 2020 Sep 11. pii: 10.1038/s41388-020-01456.
   PubMed     Abstract available
   
   
   August 2020
9. SHAH K, Gagliano T, Garland L, O'Hanlon T, et al
   Androgen receptor signaling regulates the transcriptome of prostate cancer cells by modulating global alternative splicing.
   Oncogene. 2020 Aug 20. pii: 10.1038/s41388-020-01429.
   PubMed     Abstract available
   
   
   
10. WANG Z, Li Y, Wu D, Yu S, et al
    Correction: Nuclear receptor HNF4alpha performs a tumor suppressor function in prostate cancer via its induction of p21-driven cellular senescence.
    Oncogene. 2020 Aug 20. pii: 10.1038/s41388-020-1290.
    PubMed     Abstract available
    
    
    
11. SHIN SH, Kim I, Lee JE, Lee M, et al
    Loss of EGR3 is an independent risk factor for metastatic progression in prostate cancer.
    Oncogene. 2020 Aug 14. pii: 10.1038/s41388-020-01418.
    PubMed     Abstract available
    
    
    
12. KO CJ, Hsu TW, Wu SR, Lan SW, et al
    Inhibition of TMPRSS2 by HAI-2 reduces prostate cancer cell invasion and metastasis.
    Oncogene. 2020 Aug 10. pii: 10.1038/s41388-020-01413.
    PubMed     Abstract available
    
    
    July 2020
13. KOHNO S, Linn P, Nagatani N, Watanabe Y, et al
    Pharmacologically targetable vulnerability in prostate cancer carrying RB1-SUCLA2 deletion.
    Oncogene. 2020 Jul 21. pii: 10.1038/s41388-020-1381.
    PubMed     Abstract available
    
    
    
14. WHITLOCK NC, Trostel SY, Wilkinson S, Terrigino NT, et al
    MEIS1 down-regulation by MYC mediates prostate cancer development through elevated HOXB13 expression and AR activity.
    Oncogene. 2020 Jul 17. pii: 10.1038/s41388-020-01389.
    PubMed     Abstract available
    
    
    June 2020
15. NOLLET EA, Cardo-Vila M, Ganguly SS, Tran JD, et al
    Androgen receptor-induced integrin alpha6beta1 and Bnip3 promote survival and resistance to PI3K inhibitors in castration-resistant prostate cancer.
    Oncogene. 2020 Jun 21. pii: 10.1038/s41388-020-1370.
    PubMed     Abstract available
    
    
    
16. KOHVAKKA A, Sattari M, Shcherban A, Annala M, et al
    AR and ERG drive the expression of prostate cancer specific long noncoding RNAs.
    Oncogene. 2020 Jun 17. pii: 10.1038/s41388-020-1365.
    PubMed     Abstract available
    
    
    May 2020
17. YADAV S, Anbalagan M, Baddoo M, Chellamuthu VK, et al
    Somatic mutations in the DNA repairome in prostate cancers in African Americans and Caucasians.
    Oncogene. 2020;39:4299-4311.
    PubMed     Abstract available
    
    
    April 2020
18. LI M, Nopparat J, Aguilar BJ, Chen YH, et al
    Intratumor delta-catenin heterogeneity driven by genomic rearrangement dictates growth factor dependent prostate cancer progression.
    Oncogene. 2020 Apr 20. pii: 10.1038/s41388-020-1281.
    PubMed     Abstract available
    
    
    
19. HE Y, Mi J, Olson A, Aldahl J, et al
    Androgen receptor with short polyglutamine tract preferably enhances Wnt/beta-catenin-mediated prostatic tumorigenesis.
    Oncogene. 2020;39:3276-3291.
    PubMed     Abstract available
    
    
    
20. LI J, Pu T, Yin L, Li Q, et al
    MAOA-mediated reprogramming of stromal fibroblasts promotes prostate tumorigenesis and cancer stemness.
    Oncogene. 2020;39:3305-3321.
    PubMed     Abstract available
    
    
    March 2020
21. GOTO Y, Ando T, Izumi H, Feng X, et al
    Muscarinic receptors promote castration-resistant growth of prostate cancer through a FAK-YAP signaling axis.
    Oncogene. 2020 Mar 23. pii: 10.1038/s41388-020-1272.
    PubMed     Abstract available
    
    
    
22. LIU J, He D, Cheng L, Huang C, et al
    p300/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer.
    Oncogene. 2020 Mar 23. pii: 10.1038/s41388-020-1270.
    PubMed     Abstract available
    
    
    
23. DE PIANO M, Manuelli V, Zadra G, Otte J, et al
    Lipogenic signalling modulates prostate cancer cell adhesion and migration via modification of Rho GTPases.
    Oncogene. 2020 Mar 5. pii: 10.1038/s41388-020-1243.
    PubMed     Abstract available
    
    
    February 2020
24. LOVERIDGE CJ, Slater S, Campbell KJ, Nam NA, et al
    BRF1 accelerates prostate tumourigenesis and perturbs immune infiltration.
    Oncogene. 2020;39:1797-1806.
    PubMed     Abstract available
    
    
    
25. CHEN X, Xiong X, Cui D, Yang F, et al
    DEPTOR is an in vivo tumor suppressor that inhibits prostate tumorigenesis via the inactivation of mTORC1/2 signals.
    Oncogene. 2020;39:1557-1571.
    PubMed     Abstract available
    
    
    
26. ALI S, Zhang Y, Zhou M, Li H, et al
    Functional deficiency of DNA repair gene EXO5 results in androgen-induced genomic instability and prostate tumorigenesis.
    Oncogene. 2020;39:1246-1259.
    PubMed     Abstract available
    
    
    January 2020
27. BROUSTAS CG, Duval AJ, Chaudhary KR, Friedman RA, et al
    Targeting MEK5 impairs nonhomologous end-joining repair and sensitizes prostate cancer to DNA damaging agents.
    Oncogene. 2020 Jan 24. pii: 10.1038/s41388-020-1163.
    PubMed     Abstract available
    
    
    
28. LEMPIAINEN JK, Manjur ABMK, Malinen M, Ketola K, et al
    BCOR-coupled H2A monoubiquitination represses a subset of androgen receptor target genes regulating prostate cancer proliferation.
    Oncogene. 2020 Jan 10. pii: 10.1038/s41388-020-1153.
    PubMed     Abstract available
    
    
    
29. WANG M, Nagle RB, Knudsen BS, Cress AE, et al
    Centrosome loss results in an unstable genome and malignant prostate tumors.
    Oncogene. 2020;39:399-413.
    PubMed     Abstract available
    
    
    December 2019
30. SARAC H, Morova T, Pires E, McCullagh J, et al
    Systematic characterization of chromatin modifying enzymes identifies KDM3B as a critical regulator in castration resistant prostate cancer.
    Oncogene. 2019 Dec 10. pii: 10.1038/s41388-019-1116.
    PubMed     Abstract available
    
    
    November 2019
31. HU L, Sun Y, Luo J, He X, et al
    Targeting TR4 nuclear receptor with antagonist bexarotene increases docetaxel sensitivity to better suppress the metastatic castration-resistant prostate cancer progression.
    Oncogene. 2019 Nov 20. pii: 10.1038/s41388-019-1070.
    PubMed     Abstract available
    
    
    
32. CHEN L, De Menna M, Groenewoud A, Thalmann GN, et al
    A NF-kB-Activin A signaling axis enhances prostate cancer metastasis.
    Oncogene. 2019 Nov 18. pii: 10.1038/s41388-019-1103.
    PubMed     Abstract available
    
    
    
33. WANG Z, Li Y, Wu D, Yu S, et al
    Nuclear receptor HNF4alpha performs a tumor suppressor function in prostate cancer via its induction of p21-driven cellular senescence.
    Oncogene. 2019 Nov 6. pii: 10.1038/s41388-019-1080.
    PubMed     Abstract available
    
    
    October 2019
34. WANG J, He C, Gao P, Wang S, et al
    HNF1B-mediated repression of SLUG is suppressed by EZH2 in aggressive prostate cancer.
    Oncogene. 2019 Oct 21. pii: 10.1038/s41388-019-1065.
    PubMed     Abstract available
    
    
    September 2019
35. FENG T, Zhao R, Sun F, Lu Q, et al
    TXNDC9 regulates oxidative stress-induced androgen receptor signaling to promote prostate cancer progression.
    Oncogene. 2019 Sep 2. pii: 10.1038/s41388-019-0991.
    PubMed     Abstract available
    
    
    
36. HE Y, Johnson DT, Yang JS, Wu H, et al
    Loss of the tumor suppressor, Tp53, enhances the androgen receptor-mediated oncogenic transformation and tumor development in the mouse prostate.
    Oncogene. 2019;38:6507-6520.
    PubMed     Abstract available
    
    
    
37. WANG S, Wang N, Yu B, Cao M, et al
    Circulating IGF-1 promotes prostate adenocarcinoma via FOXO3A/BIM signaling in a double-transgenic mouse model.
    Oncogene. 2019;38:6338-6353.
    PubMed     Abstract available
    
    
    August 2019
38. GANGULY SS, Hostetter G, Tang L, Frank SB, et al
    Notch3 promotes prostate cancer-induced bone lesion development via MMP-3.
    Oncogene. 2019 Aug 29. pii: 10.1038/s41388-019-0977.
    PubMed     Abstract available
    
    
    
39. ZHU S, Zhao D, Li C, Li Q, et al
    BMI1 is directly regulated by androgen receptor to promote castration-resistance in prostate cancer.
    Oncogene. 2019 Aug 28. pii: 10.1038/s41388-019-0966.
    PubMed     Abstract available
    
    
    
40. COOK LM, Frieling JS, Nerlakanti N, McGuire JJ, et al
    Betaglycan drives the mesenchymal stromal cell osteogenic program and prostate cancer-induced osteogenesis.
    Oncogene. 2019 Aug 13. pii: 10.1038/s41388-019-0913.
    PubMed     Abstract available
    
    
    
41. CAO S, Ma T, Ungerleider N, Roberts C, et al
    Circular RNAs add diversity to androgen receptor isoform repertoire in castration-resistant prostate cancer.
    Oncogene. 2019 Aug 13. pii: 10.1038/s41388-019-0947.
    PubMed     Abstract available
    
    
    July 2019
42. LI L, Ameri AH, Wang S, Jansson KH, et al
    EGR1 regulates angiogenic and osteoclastogenic factors in prostate cancer and promotes metastasis.
    Oncogene. 2019 Jul 16. pii: 10.1038/s41388-019-0873.
    PubMed     Abstract available
    
    
    
43. PALLMANN N, Livgard M, Tesikova M, Zeynep Nenseth H, et al
    Regulation of the unfolded protein response through ATF4 and FAM129A in prostate cancer.
    Oncogene. 2019 Jul 16. pii: 10.1038/s41388-019-0879.
    PubMed     Abstract available
    
    
    
44. TASSONE E, Bradaschia-Correa V, Xiong X, Sastre-Perona A, et al
    KLF4 as a rheostat of osteolysis and osteogenesis in prostate tumors in the bone.
    Oncogene. 2019;38:5766-5777.
    PubMed     Abstract available
    
    
    May 2019
45. LEE CF, Dang A, Hernandez E, Pong RC, et al
    Activation of sphingosine kinase by lipopolysaccharide promotes prostate cancer cell invasion and metastasis via SphK1/S1PR4/matriptase.
    Oncogene. 2019 May 31. pii: 10.1038/s41388-019-0833.
    PubMed     Abstract available
    
    
    
46. ZHU S, Tian H, Niu X, Wang J, et al
    Correction: Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer.
    Oncogene. 2019 May 2. pii: 10.1038/s41388-019-0827.
    PubMed     Abstract available
    
    
    
47. FLETCHER CE, Sulpice E, Combe S, Shibakawa A, et al
    Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer.
    Oncogene. 2019 May 1. pii: 10.1038/s41388-019-0823.
    PubMed     Abstract available
    
    
    
48. LUNA VELEZ MV, Verhaegh GW, Smit F, Sedelaar JPM, et al
    Suppression of prostate tumor cell survival by antisense oligonucleotide-mediated inhibition of AR-V7 mRNA synthesis.
    Oncogene. 2019;38:3696-3709.
    PubMed     Abstract available
    
    
    April 2019
49. COLEMAN DJ, Gao L, King CJ, Schwartzman J, et al
    BET bromodomain inhibition blocks the function of a critical AR-independent master regulator network in lethal prostate cancer.
    Oncogene. 2019 Apr 17. pii: 10.1038/s41388-019-0815.
    PubMed     Abstract available
    
    
    
50. IPPOLITO L, Morandi A, Taddei ML, Parri M, et al
    Cancer-associated fibroblasts promote prostate cancer malignancy via metabolic rewiring and mitochondrial transfer.
    Oncogene. 2019 Apr 1. pii: 10.1038/s41388-019-0805.
    PubMed     Abstract available
    
    
    
51. WANG C, Wang G, Feng X, Shepherd P, et al
    Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition.
    Oncogene. 2019;38:2451-2463.
    PubMed     Abstract available
    
    
    March 2019
52. SESHACHARYULU P, Rachagani S, Muniyan S, Siddiqui JA, et al
    FDPS cooperates with PTEN loss to promote prostate cancer progression through modulation of small GTPases/AKT axis.
    Oncogene. 2019 Mar 26. pii: 10.1038/s41388-019-0791.
    PubMed     Abstract available
    
    
    
53. SINHA KM, Bagheri-Yarmand R, Lahiri S, Lu Y, et al
    Oncogenic and osteolytic functions of histone demethylase NO66 in castration-resistant prostate cancer.
    Oncogene. 2019 Mar 11. pii: 10.1038/s41388-019-0774.
    PubMed     Abstract available
    
    
    
54. ZHOU PJ, Wang X, An N, Wei L, et al
    Loss of Par3 promotes prostatic tumorigenesis by enhancing cell growth and changing cell division modes.
    Oncogene. 2019;38:2192-2205.
    PubMed     Abstract available
    
    
    February 2019
55. BAI S, Cao S, Jin L, Kobelski M, et al
    A positive role of c-Myc in regulating androgen receptor and its splice variants in prostate cancer.
    Oncogene. 2019 Feb 28. pii: 10.1038/s41388-019-0768.
    PubMed     Abstract available
    
    
    
56. WANG Y, Li X, Liu W, Li B, et al
    MicroRNA-1205, encoded on chromosome 8q24, targets EGLN3 to induce cell growth and contributes to risk of castration-resistant prostate cancer.
    Oncogene. 2019 Feb 26. pii: 10.1038/s41388-019-0760.
    PubMed     Abstract available
    
    
    
57. ZHU S, Tian H, Niu X, Wang J, et al
    Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer.
    Oncogene. 2019 Feb 15. pii: 10.1038/s41388-019-0750.
    PubMed     Abstract available
    
    
    
58. WANG W, Yang X, Dai J, Lu Y, et al
    Prostate cancer promotes a vicious cycle of bone metastasis progression through inducing osteocytes to secrete GDF15 that stimulates prostate cancer growth and invasion.
    Oncogene. 2019 Feb 12. pii: 10.1038/s41388-019-0736.
    PubMed     Abstract available
    
    
    
59. YANG J, Guo Y, Lu C, Zhang R, et al
    Inhibition of Karyopherin beta 1 suppresses prostate cancer growth.
    Oncogene. 2019 Feb 11. pii: 10.1038/s41388-019-0745.
    PubMed     Abstract available
    
    
    
60. VENKADAKRISHNAN VB, DePriest AD, Kumari S, Senapati D, et al
    Protein Kinase N1 control of androgen-responsive serum response factor action provides rationale for novel prostate cancer treatment strategy.
    Oncogene. 2019 Feb 11. pii: 10.1038/s41388-019-0732.
    PubMed     Abstract available
    
    
    
61. ZHOU F, Gao S, Han D, Han W, et al
    TMPRSS2-ERG activates NO-cGMP signaling in prostate cancer cells.
    Oncogene. 2019 Feb 4. pii: 10.1038/s41388-019-0730.
    PubMed     Abstract available
    
    
    
62. ZHANG M, Suarez E, Vasquez JL, Nathanson L, et al
    Inositol polyphosphate 4-phosphatase type II regulation of androgen receptor activity.
    Oncogene. 2019;38:1121-1135.
    PubMed     Abstract available
    
    
    January 2019
63. ZANG G, Mu Y, Gao L, Bergh A, et al
    PKCzeta facilitates lymphatic metastatic spread of prostate cancer cells in a mice xenograft model.
    Oncogene. 2019 Jan 31. pii: 10.1038/s41388-019-0722.
    PubMed     Abstract available
    
    
    
64. COMITO G, Iscaro A, Bacci M, Morandi A, et al
    Lactate modulates CD4(+) T-cell polarization and induces an immunosuppressive environment, which sustains prostate carcinoma progression via TLR8/miR21 axis.
    Oncogene. 2019 Jan 21. pii: 10.1038/s41388-019-0688.
    PubMed     Abstract available
    
    
    
65. JANG D, Kwon H, Choi M, Lee J, et al
    Sumoylation of Flotillin-1 promotes EMT in metastatic prostate cancer by suppressing Snail degradation.
    Oncogene. 2019 Jan 10. pii: 10.1038/s41388-018-0641.
    PubMed     Abstract available
    
    
    
66. KATO M, Placencio-Hickok VR, Madhav A, Haldar S, et al
    Heterogeneous cancer-associated fibroblast population potentiates neuroendocrine differentiation and castrate resistance in a CD105-dependent manner.
    Oncogene. 2019;38:716-730.
    PubMed     Abstract available
    
    
    
67. WANG HJ, Pochampalli M, Wang LY, Zou JX, et al
    KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC.
    Oncogene. 2019;38:17-32.
    PubMed     Abstract available
    
    
    December 2018
68. XIE Y, Fan H, Lu W, Yang Q, et al
    Nuclear MET requires ARF and is inhibited by carbon nanodots through binding to phospho-tyrosine in prostate cancer.
    Oncogene. 2018 Dec 19. pii: 10.1038/s41388-018-0608.
    PubMed     Abstract available
    
    
    
69. YANG Z, Qu CB, Zhang Y, Zhang WF, et al
    Dysregulation of p53-RBM25-mediated circAMOTL1L biogenesis contributes to prostate cancer progression through the circAMOTL1L-miR-193a-5p-Pcdha pathway.
    Oncogene. 2018 Dec 7. pii: 10.1038/s41388-018-0602.
    PubMed     Abstract available
    
    
    
70. HE Y, Hooker E, Yu EJ, Cunha GR, et al
    Androgen signaling is essential for development of prostate cancer initiated from prostatic basal cells.
    Oncogene. 2018 Dec 3. pii: 10.1038/s41388-018-0583.
    PubMed     Abstract available
    
    
    
71. STYLIANOU N, Lehman ML, Wang C, Fard AT, et al
    Correction: A molecular portrait of epithelial-mesenchymal plasticity in prostate cancer associated with clinical outcome.
    Oncogene. 2018 Dec 3. pii: 10.1038/s41388-018-0587.
    PubMed     Abstract available
    
    
    November 2018
72. WENG CC, Ding PY, Liu YH, Hawse JR, et al
    Mutant Kras-induced upregulation of CD24 enhances prostate cancer stemness and bone metastasis.
    Oncogene. 2018 Nov 22. pii: 10.1038/s41388-018-0575.
    PubMed     Abstract available
    
    
    
73. PAI VC, Hsu CC, Chan TS, Liao WY, et al
    Correction: ASPM promotes prostate cancer stemness and progression by augmenting Wnt-Dvl-3-beta-catenin signaling.
    Oncogene. 2018 Nov 2. pii: 10.1038/s41388-018-0561.
    PubMed     Abstract available
    
    
    October 2018
74. SU F, Ahn S, Saha A, DiGiovanni J, et al
    Adipose stromal cell targeting suppresses prostate cancer epithelial-mesenchymal transition and chemoresistance.
    Oncogene. 2018 Oct 25. pii: 10.1038/s41388-018-0558.
    PubMed     Abstract available
    
    
    
75. PROBERT C, Dottorini T, Speakman A, Hunt S, et al
    Communication of prostate cancer cells with bone cells via extracellular vesicle RNA; a potential mechanism of metastasis.
    Oncogene. 2018 Oct 23. pii: 10.1038/s41388-018-0540.
    PubMed     Abstract available
    
    
    September 2018
76. PAI VC, Hsu CC, Chan TS, Liao WY, et al
    ASPM promotes prostate cancer stemness and progression by augmenting Wnt-Dvl-3-beta-catenin signaling.
    Oncogene. 2018 Sep 28. pii: 10.1038/s41388-018-0497.
    PubMed     Abstract available
    
    
    
77. WARREN AY, Massie CE, Watt K, Luko K, et al
    A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer.
    Oncogene. 2018 Sep 20. pii: 10.1038/s41388-018-0501.
    PubMed     Abstract available
    
    
    
78. STYLIANOU N, Lehman ML, Wang C, Fard AT, et al
    A molecular portrait of epithelial-mesenchymal plasticity in prostate cancer associated with clinical outcome.
    Oncogene. 2018 Sep 7. pii: 10.1038/s41388-018-0488.
    PubMed     Abstract available
    
    
    
79. BIRNBAUM MD, Zhao N, Moorthy BT, Patel DM, et al
    Reduced Arginyltransferase 1 is a driver and a potential prognostic indicator of prostate cancer metastasis.
    Oncogene. 2018 Sep 3. pii: 10.1038/s41388-018-0462.
    PubMed     Abstract available
    
    
    August 2018
80. LONG MD, Singh PK, Russell JR, Llimos G, et al
    The miR-96 and RARgamma signaling axis governs androgen signaling and prostate cancer progression.
    Oncogene. 2018 Aug 17. pii: 10.1038/s41388-018-0450.
    PubMed     Abstract available
    
    
    
81. SBRISSA D, Semaan L, Govindarajan B, Li Y, et al
    A novel cross-talk between CXCR4 and PI4KIIIalpha in prostate cancer cells.
    Oncogene. 2018 Aug 15. pii: 10.1038/s41388-018-0448.
    PubMed     Abstract available
    
    
    
82. MCCLURG UL, Chit NCTH, Azizyan M, Edwards J, et al
    Molecular mechanism of the TP53-MDM2-AR-AKT signalling network regulation by USP12.
    Oncogene. 2018;37:4679-4691.
    PubMed     Abstract available
    
    
    July 2018
83. XU Z, Wang Y, Xiao ZG, Zou C, et al
    Nuclear receptor ERRalpha and transcription factor ERG form a reciprocal loop in the regulation of TMPRSS2:ERG fusion gene in prostate cancer.
    Oncogene. 2018 Jul 24. pii: 10.1038/s41388-018-0409.
    PubMed     Abstract available
    
    
    
84. O'BRYANT D, Wang Z
    The essential role of WD repeat domain 77 in prostate tumor initiation induced by Pten loss.
    Oncogene. 2018;37:4151-4163.
    PubMed     Abstract available
    
    
    
85. SEIDI K, Jahanban-Esfahlan R, Monhemi H, Zare P, et al
    NGR (Asn-Gly-Arg)-targeted delivery of coagulase to tumor vasculature arrests cancer cell growth.
    Oncogene. 2018;37:3967-3980.
    PubMed     Abstract available
    
    
    June 2018
86. KIM JM, Shin Y, Lee S, Kim MY, et al
    MacroH2A1.2 inhibits prostate cancer-induced osteoclastogenesis through cooperation with HP1alpha and H1.2.
    Oncogene. 2018 Jun 20. pii: 10.1038/s41388-018-0356.
    PubMed     Abstract available
    
    
    
87. AL SHAREEF Z, Kardooni H, Murillo-Garzon V, Domenici G, et al
    Protective effect of stromal Dickkopf-3 in prostate cancer: opposing roles for TGFBI and ECM-1.
    Oncogene. 2018 Jun 1. pii: 10.1038/s41388-018-0294.
    PubMed     Abstract available
    
    
    May 2018
88. PARK JJ, Park MH, Oh EH, Soung NK, et al
    The p21-activated kinase 4-Slug transcription factor axis promotes epithelial-mesenchymal transition and worsens prognosis in prostate cancer.
    Oncogene. 2018 May 30. pii: 10.1038/s41388-018-0327.
    PubMed     Abstract available
    
    
    
89. LIAO CP, Lin TP, Li PC, Geary LA, et al
    Loss of MAOA in epithelia inhibits adenocarcinoma development, cell proliferation and cancer stem cells in prostate.
    Oncogene. 2018 May 29. pii: 10.1038/s41388-018-0325.
    PubMed     Abstract available
    
    
    
90. GARG R, Blando JM, Perez CJ, Lal P, et al
    COX-2 mediates pro-tumorigenic effects of PKCepsilon in prostate cancer.
    Oncogene. 2018 May 16. pii: 10.1038/s41388-018-0318.
    PubMed     Abstract available
    
    
    
91. MADHAV A, Andres A, Duong F, Mishra R, et al
    Antagonizing CD105 enhances radiation sensitivity in prostate cancer.
    Oncogene. 2018 May 2. pii: 10.1038/s41388-018-0278.
    PubMed     Abstract available
    
    
    
92. POLLAN SG, Huang F, Sperger JM, Lang JM, et al
    Regulation of inside-out beta1-integrin activation by CDCP1.
    Oncogene. 2018;37:2817-2836.
    PubMed     Abstract available
    
    
    March 2018
93. JIA L, Wu D, Wang Y, You W, et al
    Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription.
    Oncogene. 2018 Mar 20. pii: 10.1038/s41388-018-0198.
    PubMed     Abstract available
    
    
    
94. CHENG Y, Gao XH, Li XJ, Cao QH, et al
    Depression promotes prostate cancer invasion and metastasis via a sympathetic-cAMP-FAK signaling pathway.
    Oncogene. 2018 Mar 8. pii: 10.1038/s41388-018-0177.
    PubMed     Abstract available
    
    
    
95. LV S, Ji L, Chen B, Liu S, et al
    Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4.
    Oncogene. 2018;37:1354-1368.
    PubMed     Abstract available
    
    
    February 2018
96. LI N, Truong S, Nouri M, Moore J, et al
    Non-canonical activation of hedgehog in prostate cancer cells mediated by the interaction of transcriptionally active androgen receptor proteins with Gli3.
    Oncogene. 2018 Feb 12. pii: 10.1038/s41388-017-0098.
    PubMed     Abstract available
    
    
    January 2018
97. TAKAYAMA KI, Suzuki T, Tanaka T, Fujimura T, et al
    TRIM25 enhances cell growth and cell survival by modulating p53 signals via interaction with G3BP2 in prostate cancer.
    Oncogene. 2018 Jan 30. pii: 10.1038/s41388-017-0095.
    PubMed     Abstract available
    
    
    
98. METT V, Komarova EA, Greene K, Bespalov I, et al
    Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy.
    Oncogene. 2018;37:439-449.
    PubMed     Abstract available
    
    
    
99. STELLOO S, Nevedomskaya E, Kim Y, Hoekman L, et al
    Endogenous androgen receptor proteomic profiling reveals genomic subcomplex involved in prostate tumorigenesis.
    Oncogene. 2018;37:313-322.
    PubMed     Abstract available
    
    
    December 2017
100. MOON SJ, Jeong BC, Kim HJ, Lim JE, et al
     DBC1 promotes castration-resistant prostate cancer by positively regulating DNA binding and stability of AR-V7.
     Oncogene. 2017 Dec 18. pii: 10.1038/s41388-017-0047.
     PubMed     Abstract available
     
     
     November 2017
101. GUO Y, Cui J, Ji Z, Cheng C, et al
     miR-302/367/LATS2/YAP pathway is essential for prostate tumor-propagating cells and promotes the development of castration resistance.
     Oncogene. 2017;36:6336-6347.
     PubMed     Abstract available
     
     
     October 2017
102. HAN W, Gao S, Barrett D, Ahmed M, et al
     Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer.
     Oncogene. 2017 Oct 23. doi: 10.1038/onc.2017.
     PubMed     Abstract available
     
     
     
103. JING Y, Nguyen MM, Wang D, Pascal LE, et al
     DHX15 promotes prostate cancer progression by stimulating Siah2-mediated ubiquitination of androgen receptor.
     Oncogene. 2017 Oct 9. doi: 10.1038/onc.2017.
     PubMed     Abstract available
     
     
     
104. CHANG C, Liu J, He W, Qu M, et al
     A regulatory circuit HP1gamma/miR-451a/c-Myc promotes prostate cancer progression.
     Oncogene. 2017 Oct 2. doi: 10.1038/onc.2017.
     PubMed     Abstract available
     
     
     August 2017
105. GENG C, Kaochar S, Li M, Rajapakshe K, et al
     SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of c-MYC oncoprotein.
     Oncogene. 2017;36:4767-4777.
     PubMed     Abstract available
     
     
     July 2017
106. D'ABRONZO LS, Bose S, Crapuchettes ME, Beggs RE, et al
     The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer.
     Oncogene. 2017 Jul 24. doi: 10.1038/onc.2017.
     PubMed     Abstract available
     
     
     
107. LI Y, Wang L, Liu J, Zhang P, et al
     O-GlcNAcylation modulates Bmi-1 protein stability and potential oncogenic function in prostate cancer.
     Oncogene. 2017 Jul 17. doi: 10.1038/onc.2017.
     PubMed     Abstract available
     
     
     
108. ASHIKARI D, Takayama K, Tanaka T, Suzuki Y, et al
     Androgen induces G3BP2 and SUMO-mediated p53 nuclear export in prostate cancer.
     Oncogene. 2017 Jul 10. doi: 10.1038/onc.2017.
     PubMed     Abstract available
     
     
     
109. CHEN WY, Tsai YC, Siu MK, Yeh HL, et al
     Inhibition of the androgen receptor induces a novel tumor promoter, ZBTB46, for prostate cancer metastasis.
     Oncogene. 2017 Jul 10. doi: 10.1038/onc.2017.
     PubMed     Abstract available
     
     
     
110. VALENTINO A, Calarco A, Di Salle A, Finicelli M, et al
     Deregulation of MicroRNAs mediated control of carnitine cycle in prostate cancer: molecular basis and pathophysiological consequences.
     Oncogene. 2017 Jul 3. doi: 10.1038/onc.2017.
     PubMed     Abstract available
     
     
     June 2017
111. CANNISTRACI A, Federici G, Addario A, Di Pace AL, et al
     C-Met/miR-130b axis as novel mechanism and biomarker for castration resistance state acquisition.
     Oncogene. 2017;36:3718-3728.
     PubMed     Abstract available
     
     
     
112. TSE BWC, Volpert M, Ratther E, Stylianou N, et al
     Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality.
     Oncogene. 2017;36:3417-3427.
     PubMed     Abstract available
     
     
     
113. PIXBERG CF, Raba K, Muller F, Behrens B, et al
     Analysis of DNA methylation in single circulating tumor cells.
     Oncogene. 2017;36:3223-3231.
     PubMed     Abstract available
     
     
     
114. PISTORE C, Giannoni E, Colangelo T, Rizzo F, et al
     DNA methylation variations are required for epithelial-to-mesenchymal transition induced by cancer-associated fibroblasts in prostate cancer cells.
     Oncogene. 2017 Jun 5. doi: 10.1038/onc.2017.
     PubMed     Abstract available
     
     
     May 2017
115. YANG J, Lu C, Wei J, Guo Y, et al
     Inhibition of KPNA4 attenuates prostate cancer metastasis.
     Oncogene. 2017;36:2868-2878.
     PubMed     Abstract available
     
     
     
116. MCCURDY SR, Pacal M, Ahmad M, Bremner R, et al
     A CDK2 activity signature predicts outcome in CDK2-low cancers.
     Oncogene. 2017;36:2491-2502.
     PubMed     Abstract available
     
     
     April 2017
117. ZONI E, Chen L, Karkampouna S, Granchi Z, et al
     CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer.
     Oncogene. 2017 Apr 10. doi: 10.1038/onc.2017.
     PubMed     Abstract available
     
     
     
118. DI GIACOMO V, Tian TV, Mas A, Pecoraro M, et al
     DeltaNp63alpha promotes adhesion of metastatic prostate cancer cells to the bone through regulation of CD82.
     Oncogene. 2017 Apr 3. doi: 10.1038/onc.2017.
     PubMed     Abstract available
     
     
     
119. KO CJ, Lan SW, Lu YC, Cheng TS, et al
     Inhibition of cyclooxygenase-2-mediated matriptase activation contributes to the suppression of prostate cancer cell motility and metastasis.
     Oncogene. 2017 Apr 3. doi: 10.1038/onc.2017.
     PubMed     Abstract available
     
     
     
120. AI J, Pascal LE, Wei L, Zang Y, et al
     EAF2 regulates DNA repair through Ku70/Ku80 in the prostate.
     Oncogene. 2017;36:2054-2065.
     PubMed     Abstract available
     
     
     March 2017
121. RUAN D, He J, Li CF, Lee HJ, et al
     Skp2 deficiency restricts the progression and stem cell features of castration-resistant prostate cancer by destabilizing Twist.
     Oncogene. 2017 Mar 27. doi: 10.1038/onc.2017.
     PubMed     Abstract available
     
     
     
122. KIM J, Jin H, Zhao JC, Yang YA, et al
     FOXA1 inhibits prostate cancer neuroendocrine differentiation.
     Oncogene. 2017 Mar 20. doi: 10.1038/onc.2017.
     PubMed     Abstract available
     
     
     
123. DART AE, Worth DC, Muir G, Chandra A, et al
     The drebrin/EB3 pathway drives invasive activity in prostate cancer.
     Oncogene. 2017 Mar 20. doi: 10.1038/onc.2017.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: